Biomarker Assessments in High-Risk Patients with Diabetes
This secondary analysis of a randomized clinical trial uses data from SAVOR-TIMI 53 to assess the incremental prognostic value of biomarkers that reflect different pathophysiologic processes in patients with type 2 diabetes.